Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients
Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients
复制标题
DOI：
10.1093/eurheartj/ehi310
复制
发表时间：
2005-10-01
影响因子：
39.3
通讯作者：
Behar, S
中科院分区：
文献类型：
--
作者：
Tenenbaum, A;Motro, M;Behar, S
目的：评估纤维酸衍生物苯扎贝特对肥胖患者2型糖尿病发病率的影响，随访时间中位数为6.3年。方法和结果：研究样本包括339名非糖尿病肥胖患者（体重指数>= 30.0 kg/m2），年龄42-74岁。患者接受苯扎贝特缓释剂400 mg（178例患者）或安慰剂（161例患者）每日一次。98例患者记录了新发糖尿病：安慰剂组56例（37.0%）vs苯扎贝特组42例（27.1%）（P对数秩=0.01）。与安慰剂组相比，苯扎贝特组患者新发糖尿病的中位时间（四分位距）显著延迟：4.0（2.1-5.0）年vs. 2.0（0.5-3.5）年，P=0.002。多变量分析确定苯扎贝特治疗是新发糖尿病风险降低的独立预测因素，风险比（HR）为0.59 [95%置信区间（CI）为0.39-0.91]。其他与肥胖患者未来显性2型糖尿病相关的重要变量是甘油三酯（50 mg/dL增量），HR 1.15（95% CI 1.02-1.28）和空腹血糖（10 mg/dL增量），HR 2.27结论苯扎贝特可降低肥胖患者2型糖尿病的发病率，并能延缓肥胖患者2型糖尿病的发生。
Aims To assess the effect of fibric acid derivative bezafibrate on incidence of type 2 diabetes in obese patients over a median 6.3 years follow-up period.Methods and results The study sample comprised 339 non-diabetic obese patients (body mass index >= 30.0 kg/m(2)) aged 42-74. Patients received either bezafibrate retard 400 mg (178 patients) or placebo (161 patients) once daily. Development of new diabetes was recorded in 98 patients: in 56 (37.0%) from the placebo group vs. 42 (27.1%) from the bezafibrate group, (P log-rank=0.01). The median time (interquartile range) until onset of new diabetes was significantly delayed in patients on bezafibrate when compared with those on placebo: 4.0 (2.1-5.0) vs. 2.0 (0.5-3.5) years, P=0.002. Multivariable analysis identified bezafibrate treatment as an independent predictor of reduced risk of new diabetes with hazard ratio (HR) 0.59 [95% confidence interval (CI) 0.39-0.91]. Other significant variables associated with future overt type 2 diabetes in obese patients were triglycerides (50 mg/dL increment) with HR 1.15 (95% CI 1.02-1.28) and fasting glucose (10 mg/dL increment) with HR 2.27 (95% CI 1.83-2.81).Conclusion Bezafibrate, when compared with placebo, reduced the incidence and delayed the onset of type 2 diabetes in obese patients over a long-term follow-up period.